When rash challenges treatment: reintroducing cystic fibrosis modulator therapy safely
{{output}}
Various adverse reactions to elexacaftor/tezacaftor/ivacaftor (ETI) therapy have been documented in the literature. Here, we present the first reported case in Croatia of severe rash following ETI therapy in a 19-year-old female cystic fibrosis (CF) patient. T... ...
